glp 1 agonist moa The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Frontiers | Mechanisms of action
Description
Rodriguez, conducted a cohort study involving 125,474 patients who started GLP-1 medications, including Victoza (liraglutide), Ozempic and Wegovy, and Mounjaro and Zepbound between January 1, 2018 and December 31, 2023
If you have specific concerns or a situation arises in which you require medical advice, you should consult with an appropriately trained and qualified medical services provider.
Diab Obes Metab
Hematology and Cell Therapy, Bristol Myers Squibb
In a small retrospective study of 188 pregnancies, mean gestational weight gain was greater in women exposed to GLP-1 prior to pregnancy than unexposed women (11.3 5.4 vs 8.6 7.8 kg, 95% CI 0.6011.1) [58]
Acknowledgements This work was funded by a Heart and Stroke New Investigator Award and CIHR Project Grant (RN494769-488244)
